Key Highlights

  • TRex Bio (NASDAQ:TRXB) is set to price an 8.33 million share IPO at 14 to 16 dollars on October 9, with Eli Lilly indicating interest in acquiring up to a 19.9 percent stake.
  • Retension Pharmaceuticals (NASDAQ:RTSN) plans a smaller 3.3 million share IPO at 11 to 13 dollars, implying about 39.6 million dollars in gross proceeds, expected to trade the same day, alongside a 100 million dollar AfterNext Acquisition I SPAC scheduled for October 7.
  • SU Group Holdings (NASDAQ:SUGP) began trading on a 1-for-6 Reverse Stock Split basis on October 7 to support Nasdaq listing compliance, a different kind of market entry event tied to maintaining rather than achieving a listing.
  • Together these three events describe a thin week for new capital-raising listings overall, with TRex Bio's pharma-backed deal standing out as the most significant by both scale and anchor investor quality.

TRex Bio (NASDAQ:TRXB): A Pharma-Backed Anchor Headlines the Week

Eli Lilly's indicated interest in acquiring up to a 19.9 percent stake in TRex Bio through its IPO represents one of the more notable pharma-backed anchor investments in recent biotech listings, since large pharmaceutical companies typically reserve this kind of significant ownership interest for platforms they view as scientifically differentiated or strategically relevant. TRex Bio (NASDAQ:TRXB)'s planned sale of 8.33 million shares at 14 to 16 dollars implies gross proceeds of roughly 117 million to 133 million dollars before expenses, a mid-sized biotech offering whose final pricing, and whether Eli Lilly's actual allocation matches its indicated interest, will only be confirmed once the deal formally prices on October 9.

Retension Pharmaceuticals (NASDAQ:RTSN): A Smaller Offering in a Thin Week

Retension Pharmaceuticals' planned 3.3 million share offering at 11 to 13 dollars, implying about 39.6 million dollars in gross proceeds, is a notably smaller deal than TRex Bio's, even within the already modest biotech micro-cap IPO category. A sub-40-million-dollar raise typically funds a narrow set of near-term clinical milestones, meaning Retension Pharmaceuticals (NASDAQ:RTSN) will likely need to return to Capital markets again relatively soon if its pipeline requires substantial further investment. The separate 100 million dollar AfterNext Acquisition I blank check company, scheduled to price October 7, represents a fundamentally different Investment proposition, backing a sponsor team's future deal-sourcing ability rather than an existing, named operating Business like Retension Pharmaceuticals (NASDAQ:RTSN) itself.

SU Group Holdings (NASDAQ:SUGP): A Different Kind of Market Event

SU Group Holdings' 1-for-6 reverse stock split, effective October 7, stands apart from the other two events described here because it addresses maintaining an existing Nasdaq listing rather than achieving a new one, consolidating shares to meet a minimum bid price requirement. This type of corporate action does not change SU Group Holdings (NASDAQ:SUGP)'s underlying market Capitalization or business fundamentals, but reverse splits undertaken for compliance purposes are generally viewed as a leading indicator of prior share price weakness significant enough to risk delisting, a different kind of signal than the capital-raising optimism typically associated with a fresh IPO.

A Thin Week Overall for Genuine New Capital Raises

Taken together, this week's listings activity skews toward one substantive new offering, TRex Bio, backed by a credible pharma anchor, alongside a smaller biotech raise in Retension Pharmaceuticals, an unrelated blank check company in AfterNext Acquisition I, and a compliance-driven reverse split in SU Group Holdings that is not a capital-raising event at all. Investors should treat TRex Bio as the clearest headline story of the group given both its larger scale and the quality of its anchor investor, while recognizing that Retension Pharmaceuticals and the AfterNext SPAC represent much smaller, higher-risk propositions typical of a quiet issuance week.

Where Things Stand

TRex Bio's Eli Lilly-backed offering stands out as the most significant listing this week, both in deal size and anchor investor quality, while Retension Pharmaceuticals' smaller raise and the unrelated AfterNext Acquisition I SPAC round out an otherwise thin week for new capital-raising listings. SU Group Holdings' reverse split is a distinct category of event entirely, reflecting listing compliance rather than new capital formation. The balance of evidence favors watching TRex Bio's October 9 pricing most closely, with confirmation of Eli Lilly's final allocation the key detail still outstanding. Investors should also confirm whether both TRex Bio and Retension Pharmaceuticals hold their stated October 9 trading dates and whether AfterNext Acquisition I priced as scheduled, since IPO and SPAC timelines frequently shift based on last-minute Demand signals or sponsor decisions.